Segmented regression analysis of time to intravenous antimicrobial administration (IVA) at intervention and control sites during the implementation period. by J Mark Ansermino (13958512)

Subjects:

Interrupted time series analysis showing time to intravenous antimicrobials (IVA) in minutes at intervention and control sites in Uganda during baseline and implementation periods. by J Mark Ansermino (13958512)

Subjects:

Kenya: Enrolment, time to IVA, mortality, admissions and readmissions at sites in Kenya. by J Mark Ansermino (13958512)

Subjects:

Uganda: enrolment, time to IVA, mortality, admissions and readmissions. by J Mark Ansermino (13958512)

Subjects:

Interrupted time series analysis showing time to intravenous antimicrobials (IVA) in minutes at intervention and control sites in Kenya during baseline and implementation periods. by J Mark Ansermino (13958512)

Subjects:

Bluetooth beacons with colour coded lanyards. by J Mark Ansermino (13958512)

Subjects:

Flow diagram of the Smart Triage multisite interventional study in Uganda and Kenya indicating the progress through study phases at each site. by J Mark Ansermino (13958512)

Subjects:

Lymphocyte proliferation assay following combination therapy with NDV. by Hedieh Zargaran (21410233)

Tumor volume measurements. by Hedieh Zargaran (21410233)

DataSheet1_Significant nocturnal wakefulness after sleep onset in metabolic dysfunction–associated steatotic liver disease.PDF by Sofia Schaeffer (20379954)

“…HC 8.5 vs. 5.5, p = 0.0036), longer wakefulness after sleep onset (MASLD vs. HC 45.4 min vs. 21.3 min, p = 0.0004), and decreased sleep efficiency (MASLD vs. …”

DataSheet3_Significant nocturnal wakefulness after sleep onset in metabolic dysfunction–associated steatotic liver disease.PDF by Sofia Schaeffer (20379954)

“…HC 8.5 vs. 5.5, p = 0.0036), longer wakefulness after sleep onset (MASLD vs. HC 45.4 min vs. 21.3 min, p = 0.0004), and decreased sleep efficiency (MASLD vs. …”

DataSheet2_Significant nocturnal wakefulness after sleep onset in metabolic dysfunction–associated steatotic liver disease.PDF by Sofia Schaeffer (20379954)

“…HC 8.5 vs. 5.5, p = 0.0036), longer wakefulness after sleep onset (MASLD vs. HC 45.4 min vs. 21.3 min, p = 0.0004), and decreased sleep efficiency (MASLD vs. …”

DataSheet4_Significant nocturnal wakefulness after sleep onset in metabolic dysfunction–associated steatotic liver disease.PDF by Sofia Schaeffer (20379954)

“…HC 8.5 vs. 5.5, p = 0.0036), longer wakefulness after sleep onset (MASLD vs. HC 45.4 min vs. 21.3 min, p = 0.0004), and decreased sleep efficiency (MASLD vs. …”

IL-10 levels in tumor lysates post-treatment. by Hedieh Zargaran (21410233)

Median ± IQR <i>M. plutonius</i> bacterial load (CFU/bee) of newly emerged summer worker bees inoculated with 1 × 10⁷ CFU/bee <i>M. plutonius</i> 2019BC1 and/or treated... by Midhun Sebastian Jose (19336846)

CTL response following combination therapy with NDV. by Hedieh Zargaran (21410233)

电针预处理通过心肌缺血损伤 棕色脂肪组织和 BMP3b/Smad1/5 通路小鼠 by Danying Qian (21730250)

Subjects: “…electroacupuncture significantly decreased…”

Box plots showing the taxa that were significantly different between thin and normal cows. by Bhuripit Saraphol (20855573)

Subjects:

ELISA analysis revealed a significant decrease in SP (A & B) and CGRP (C & D) protein levels in the corneas and tear fluid of mice treated with 0.5% bupivacaine (BUP) every alternate day for 15 days (administered via subconjunctival injection (SCI) alone or in combination with topical (TOP) application) compared to PBS-treated controls. by Ananya Datta (19932144)

The (A) logistic regression model (LRM) and (B) random forest model (RFM) with only conservation scores as independent variables (orange, yellow) show decreased model fitting metri... by Bushra Haque (20513785)